Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 21.10.2024 1 Am J Respir Crit Care Med 4 Ann Oncol 2 Ann Thorac Surg 2 Arch Bronconeumol 3 BMC Cancer 1 Cancer Cell 1 Clin Cancer Res 1 Clin Lung Cancer 2 Eur J Cancer 1 Eur J Cardiothorac Surg 1 Genes Chromosomes Cancer 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Clin Oncol 2 J Surg Oncol 4 J Thorac Cardiovasc Surg 1 J Thorac Oncol 1 Lancet Oncol 1 Lung Cancer 1 Mol Cancer Ther 2 Mol Carcinog 1 Oncol Rep 1 Oncologist 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Respir Crit Care Med

1. LEE YC, Chang KY, Mirsaeidi M
   Associations of Social Determinants and Community Resilience with Lung Cancer Incidence and Mortality in the US.
   Am J Respir Crit Care Med. 2024 Oct 17. doi: 10.1164/rccm.202404-0798.
   PubMed        
   
   

   
   Ann Oncol

2. HARRIS E, Taflin NF, Chitkara A, Tagliamento M, et al
   Time to rethink platinum choices in the era of immunotherapy in lung cancer.
   Ann Oncol. 2024 Oct 10:S0923-7534(24)04058-4. doi: 10.1016/j.annonc.2024.
   PubMed        
   
   
3. NISHIMURA T, Fujimoto H
   PFS, OS or toxicity: What is the most important factor in the treatment of EGFR-mutated lung cancer?
   Ann Oncol. 2024 Oct 11:S0923-7534(24)04059-6. doi: 10.1016/j.annonc.2024.
   PubMed        
   
   
4. MEYER ML, Peters S, Mok TS, Lam S, et al
   Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action.
   Ann Oncol. 2024 Oct 14:S0923-7534(24)04055-9. doi: 10.1016/j.annonc.2024.
   PubMed         Abstract available
   
   
5. JOHN A, McDonald F, Popat S
   Inoperable Stage III EGFR Mutant Non-Small Cell Lung Cancer: time for drug first, local later?
   Ann Oncol. 2024 Oct 10:S0923-7534(24)04054-7. doi: 10.1016/j.annonc.2024.
   PubMed        
   
   

   
   Ann Thorac Surg

6. LI X, Li Q, Yang F, Gao E, et al
   Survival Outcomes of Neoadjuvant Therapy Followed by Sleeve Lobectomy in Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2024 Oct 17:S0003-4975(24)00863.
   PubMed         Abstract available
   
   
7. KIM SS, Cooke DT, Kidane B, Tapias LF, et al
   The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2024 Oct 16:S0003-4975(24)00861.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

8. ZHAO S, Li B, Yu Z, Du J, et al
   Individual and Structural Factors Influencing Participation to Low-Dose Computed Tomography Screening in a Chinese Centralized Lung Cancer Screening Cohort.
   Arch Bronconeumol. 2024 Oct 9:S0300-2896(24)00370.
   PubMed        
   
   
9. GARCIA-DIAZ A, Moyano-Rodriguez MJ, Garrido-Navas MDC, de Miguel-Perez D, et al
   Resectable Non-Small Cell Lung Cancer Heterogeneity and Recurrence Assessed by Tissue Next-Generation Sequencing Genotyping and Circulating Tumor Cell EZH2 Characterization.
   Arch Bronconeumol. 2024 Oct 4:S0300-2896(24)00360.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. SUGAI K, Mori T, Bilal T, Furukawa A, et al
    Detection of circulating tumor cells in patients with lung cancer using a rare cell sorter: a pilot study.
    BMC Cancer. 2024;24:1291.
    PubMed         Abstract available
    
    
11. YU Q, Yang H, Xiao F, Wang Z, et al
    Network meta-analysis on the efficacy and safety of management for resectable stage IIIA-N2 non-small cell lung cancer.
    BMC Cancer. 2024;24:1286.
    PubMed         Abstract available
    
    
12. WANG F, Liu J, Liao W, Zheng L, et al
    Matrine alkaloids modulating DNA damage repair in chemoresistant non-small cell lung cancer cells.
    BMC Cancer. 2024;24:1283.
    PubMed         Abstract available
    
    

    
    Cancer Cell

13. FU M, Zhao J, Zhang L, Sheng Z, et al
    Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade.
    Cancer Cell. 2024 Oct 9:S1535-6108(24)00360-X. doi: 10.1016/j.ccell.2024.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

14. STEWART CA, Diao L, Xi Y, Wang R, et al
    YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.
    Clin Cancer Res. 2024;30:4743-4754.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

15. RSHAIDAT H, Mack SJ, Koeneman SH, Martin J, et al
    The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients With Lung Cancer.
    Clin Lung Cancer. 2024 Sep 24:S1525-7304(24)00202.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

16. SAALFELD FC, Moller J, Christopoulos P, Wenzel C, et al
    Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Eur J Cancer. 2024;213:115065.
    PubMed         Abstract available
    
    
17. LEONETTI A, Perrone F, Puntoni M, Maglietta G, et al
    Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024 Oct 2:115057. doi: 10.1016/j.ejca.2024.115057.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

18. HOJSKI A, Kramer M, Gecas P, Djakovic Z, et al
    The efficacy of loco-regional ropivacaine analgesia via intercostal catheters after lung resection: a randomized, double-blind, placebo-controlled, superiority study.
    Eur J Cardiothorac Surg. 2024;66:ezae342.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

19. KATO K, Goto H, Tanaka M, Suzuki T, et al
    Establishment and Characterization of a Novel Pleuropulmonary Blastoma Cell Line.
    Genes Chromosomes Cancer. 2024;63:e23276.
    PubMed         Abstract available
    
    

    
    Int J Cancer

20. JEMAL A, Schafer EJ, Star J, Bandi P, et al
    Lung cancer incidence rates in young women and men by state in the United States.
    Int J Cancer. 2024 Oct 11. doi: 10.1002/ijc.35188.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

21. ZHAO X, Huang S, Lin H, Choi JI, et al
    A Novel Dose Rate Optimization Method to Maximize Ultrahigh-Dose-Rate Coverage of Critical Organs at Risk Without Compromising Dosimetry Metrics in Proton Pencil Beam Scanning FLASH Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;120:1181-1191.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

22. YANG L, Li M, Liu Y, Jiang Z, et al
    Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:453.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

23. LEIGHL NB, Akamatsu H, Lim SM, Cheng Y, et al
    Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
    J Clin Oncol. 2024;42:3593-3605.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

24. LIANG XL, Li XB, Fu YB, Su YD, et al
    Research progress of malignant peritoneal mesothelioma with paraneoplastic syndrome: A review.
    J Surg Oncol. 2024;130:533-542.
    PubMed         Abstract available
    
    
25. VITELLO DJ, Logan CD, Zaza NN, Bates KR, et al
    Comparison of a Risk Calculator With Frailty Indices in Patients Undergoing Lung Cancer Resection.
    J Surg Oncol. 2024 Oct 10. doi: 10.1002/jso.27861.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

26. HUTCHINGS H, Boyajian H, Okereke I
    Reply: Achieving environmental justice will reduce lung cancer health disparities.
    J Thorac Cardiovasc Surg. 2024 Oct 9:S0022-5223(24)00766.
    PubMed        
    
    
27. BRUNELLI A, Antonoff MB, Petersen RH, Stiles BM, et al
    Surgeon preferences for self-treatment in locally advanced non-small cell lung cancer: Would we practice what we preach?
    J Thorac Cardiovasc Surg. 2024 Sep 19:S0022-5223(24)00526.
    PubMed        
    
    
28. RABINOVICH EP, Martin LW
    Getting Patients to Adjuvant Therapy after Lung Cancer Resection: ERAS Protocols and Return to Intended Oncologic Therapy.
    J Thorac Cardiovasc Surg. 2024 Oct 10:S0022-5223(24)00916.
    PubMed        
    
    
29. GALVAING G, Drevet G, Tricard J, Gregoire J, et al
    Lung cancer invading the chest wall: The role of site of chest wall invasion.
    J Thorac Cardiovasc Surg. 2024 Oct 17:S0022-5223(24)00826.
    PubMed        
    
    

    
    J Thorac Oncol

30. UMEMURA S, Udagawa H, Ikeda T, Murakami H, et al
    Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib.
    J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

31. PROVENCIO M, Nadal E, Insa A, Garcia Campelo R, et al
    Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2024 Oct 14:S1470-2045(24)00498.
    PubMed         Abstract available
    
    

    
    Lung Cancer

32. KATO Y, Udagawa H, Matsumoto S, Izumi H, et al
    Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
    Lung Cancer. 2024;197:107992.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

33. CINA C, Majeti B, O'Brien Z, Wang L, et al
    A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-driven Non-small Cell Lung Cancer.
    Mol Cancer Ther. 2024 Oct 17. doi: 10.1158/1535-7163.MCT-23-0915.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

34. QIU R, Deng Y, Lu Y, Liu X, et al
    ITGB3-enriched extracellular vesicles mediate the formation of osteoclastic pre-metastatic niche to promote lung adenocarcinoma bone metastasis.
    Mol Carcinog. 2024;63:2190-2204.
    PubMed         Abstract available
    
    
35. ZHANG Y, Wang Y, Weng J, Chen J, et al
    Pyroptosis-related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma.
    Mol Carcinog. 2024;63:2218-2236.
    PubMed         Abstract available
    
    

    
    Oncol Rep

36. WEI Q, Lin J, Lin Z, Yu N, et al
    GOLPH3 inhibition overcomes cisplatin resistance by restoring the glutathione/reactive oxygen species balance in the A549 non?small cell lung cancer cell line.
    Oncol Rep. 2024;52:170.
    PubMed         Abstract available
    
    

    
    Oncologist

37. ARRIETA O, Ramos-Ramirez M, Garces-Flores H, Cabrera-Miranda LA, et al
    Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries.
    Oncologist. 2024 Oct 19:oyae272. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

38. PENG J, Xu H, Liu Q
    Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
    PLoS One. 2024;19:e0312133.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

39. ZHU J, Du W, Zeng Y, Liu T, et al
    CD73 promotes non-small cell lung cancer metastasis by regulating Axl signaling independent of GAS6.
    Proc Natl Acad Sci U S A. 2024;121:e2404709121.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.